Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • ascls.org
    • ascls.org

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society for Clinical Laboratory Science
  • ascls.org
    • ascls.org
  • My alerts
  • Log in
  • My Cart
American Society for Clinical Laboratory Science

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • Follow ASCLS on Twitter
  • Visit ASCLS on Facebook
  • Follow ASCLS on Instagram
  • RSS Feed
IntroductionFocus: Methicillin-Resistant Staphylococus Aureus (MRSA)

Introduction

Wanda Reygaert
American Society for Clinical Laboratory Science April 2009, 22 (2) 109-110; DOI: https://doi.org/10.29074/ascls.22.2.109
Wanda Reygaert
is assistant professor, Medical Laboratory Science Program, Oakland University, Rochester, MI
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: reygaert@oakland.edu
  • Article
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

  1. Wanda Reygaert, PhD⇑
    1. is assistant professor, Medical Laboratory Science Program, Oakland University, Rochester, MI
  1. Address for Correspondence: Wanda Reygaert, PhD, Assistant Professor ,Oakland University,School of Health Sciences,Medical Laboratory Science Program,Rochester, Michigan 48309, reygaert{at}oakland.edu

Extract

Staphylococcus aureus is a non-motile, gram-positive cocci that colonizes in clusters. It is found world wide and is a leading cause of disease. It can normally only transiently colonize the outside and entry portals of the human body (skin, ears, eye, nasal passages, etc.), but it is estimated that 20% of humans are carriers (asymptomatic permanent colonization)1. However, even transient colonization can lead to infection if the conditions are right; such as a breach in the protective layer of epithelial cells, or a compromised immune system. The ability to cause disease is via two mechanisms: 1) toxin production, and/or 2) proliferation of the organism, which causes tissue destruction.

Most infections remain localized at entry portals and are usually self-limiting and non-life threatening. Much less frequently, more serious infections may occur when the organism is able to invade deeper into the body (osteomyelitis, septicemia, pneumonia, etc.) (Fig. 1). These deeper infections may be extremely serious and even fatal. Because infections of S. aureus occur at a higher rate than that of many bacteria, the costs that are incurred for hospitalization and treatment can be tremendous. In just one year, 1995, in New York City, it was estimated that there were at least 13,550 cases of S. aureus infections resulting in an estimated cost of about $435.5 million2.

In a study that was published in 2007 with data from the year 2003, it was found that nearly 390,000 people in the U.S. were hospitalized with S. aureus infections, with the average hospital…

    INDEX TERMS
  • MRSA
  • methicillin-resistance
  • Staphylococcus aureus
  • © Copyright 2009 American Society for Clinical Laboratory Science Inc. All rights reserved.
PreviousNext
Back to top

In this issue

American Society for Clinical Laboratory Science: 22 (2)
American Society for Clinical Laboratory Science
Vol. 22, Issue 2
Spring 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Society for Clinical Laboratory Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Introduction
(Your Name) has sent you a message from American Society for Clinical Laboratory Science
(Your Name) thought you would like to see the American Society for Clinical Laboratory Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Introduction
Wanda Reygaert
American Society for Clinical Laboratory Science Apr 2009, 22 (2) 109-110; DOI: 10.29074/ascls.22.2.109

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Introduction
Wanda Reygaert
American Society for Clinical Laboratory Science Apr 2009, 22 (2) 109-110; DOI: 10.29074/ascls.22.2.109
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Methicillin-Resistant Staphylococcus aureus (MRSA): Prevalence and Epidemiology Issues
  • Methicillin-Resistant Staphylococcus aureus (MRSA): Molecular Aspects of Antimicrobial Resistance and Virulence
Show more Focus: Methicillin-Resistant Staphylococus Aureus (MRSA)

Similar Articles

Keywords

  • MRSA
  • methicillin-resistance
  • Staphylococcus aureus

© 2025 The American Society for Clinical Laboratory Science

Powered by HighWire